Marksans Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Marksans Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹80Over the last 3 years, every ₹100 of reported profit came with ₹80 of operating cash.
Lower than 72% of Healthcare companies in India.
Self-Funding Ratio
1.7×Over the last 3 years its own operating cash covered its investment spending (capex) 1.7 times.
Higher than 63% of Healthcare companies in India.
Cash Locked Ratio
₹41For every ₹100 of sales, ₹41 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹35 tied up three years earlier.
More money tied up than 80% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹14Sales grew 59% in 3 years; of every extra ₹100 of sales, ₹14 became extra profit.
Lower than 59% of Healthcare companies in India.
Asset Productivity Ratio
+59% / +76%In 3 years sales changed by +59% while total assets changed by +76%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
15.5×Debt due within a year is covered 15.5 times by its yearly operating cash.
Higher than 80% of Healthcare companies in India.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Higher than 80% of Healthcare companies in India.
Tangible Assets Ratio
96%Of every ₹100 the company owns, ₹96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 58% of Healthcare companies in India.
Tangible Net Worth Ratio
95%Of every ₹100 of net worth, ₹95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 52% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Marksans Pharma Limited owes ₹0.21 for every ₹1 it owns. Net profit rose 10% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
25.8Investors pay ₹25.8 for every ₹1 of Marksans Pharma Limited's yearly profit, lower than 72% of Healthcare companies in India.
P/B ratio
4.41The share price is 4.41 times Marksans Pharma Limited's book value per share, lower than 55% of Healthcare companies in India.
Market cap
₹13,343 CrThe total market value of all of Marksans Pharma Limited's shares at today's price (share price × number of shares), larger than 67% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹3,023 CrWhat Marksans Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹66.71Net worth divided by the number of shares. The share price of ₹294.45 is 4.4 times this, which is the P/B above.
Return on equity (ROE)
17.1%Marksans Pharma Limited earned 17.1% on its shareholders' money over the last year, higher than 67% of Healthcare companies in India.
Owes vs Owns
0.21×Marksans Pharma Limited owes ₹0.21 for every ₹1 it owns (low), lower than 81% of Healthcare companies in India.
Dividend yield
0.29%Marksans Pharma Limited pays 0.29% of its share price as dividends a year, lower than 59% of dividend-paying Healthcare companies in India.
Revenue growth
+13%Revenue rose 13% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit growth
+10%Net profit rose 10% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Profit margin
14.2%Marksans Pharma Limited keeps ₹14 of every ₹100 of revenue as net profit.
Cash quality
1.10×Cash from Marksans Pharma Limited's business was 1.10× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
21.4×Marksans Pharma Limited's operating profit covered its interest costs 21.4 times in the year to Mar 2026.
Cash vs debt
Net cashMarksans Pharma Limited held ₹646 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Marksans Pharma Limited's P/E ratio?
Investors pay ₹25.8 for every ₹1 of Marksans Pharma Limited's yearly profit, lower than 72% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Marksans Pharma Limited: ₹13,343 Cr ÷ ₹3,023 Cr (31 Mar 2026) = 4.4.
What is Marksans Pharma Limited's return on equity?
Marksans Pharma Limited earned 17.1% on its shareholders' money over the last year, higher than 67% of Healthcare companies in India.
How much does Marksans Pharma Limited owe compared with what it owns?
Marksans Pharma Limited owes ₹0.21 for every ₹1 it owns (low), lower than 81% of Healthcare companies in India.
Does Marksans Pharma Limited pay a dividend?
Yes. Marksans Pharma Limited pays 0.29% of its share price as dividends a year, lower than 59% of dividend-paying Healthcare companies in India.
Is Marksans Pharma Limited's revenue growing?
Revenue rose 13% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.